CTI BioPharma (NASDAQ:CTIC) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.28, MarketWatch Earnings reports. CTI BioPharma had a negative net margin of 361.97% and a negative return on equity of 85.84%. The company had revenue of $14.11 million during the quarter.
Shares of NASDAQ CTIC traded up $0.01 during mid-day trading on Thursday, reaching $1.01. 1,566 shares of the company were exchanged, compared to its average volume of 391,055. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.58 and a current ratio of 3.58. The stock has a market cap of $57.99 million, a PE ratio of -0.81 and a beta of 1.59. CTI BioPharma has a twelve month low of $0.60 and a twelve month high of $5.36.
A number of brokerages have recently commented on CTIC. Lake Street Capital began coverage on shares of CTI BioPharma in a research report on Tuesday, March 5th. They issued a “buy” rating and a $4.00 price objective for the company. Oppenheimer set a $4.00 price objective on shares of CTI BioPharma and gave the company a “buy” rating in a research report on Friday, December 28th. Finally, ValuEngine raised shares of CTI BioPharma from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. CTI BioPharma presently has an average rating of “Buy” and an average price target of $5.67.
COPYRIGHT VIOLATION WARNING: “CTI BioPharma (CTIC) Releases Earnings Results, Beats Estimates By $0.28 EPS” was originally published by WKRB News and is the sole property of of WKRB News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.wkrb13.com/2019/03/14/cti-biopharma-ctic-releases-earnings-results-beats-estimates-by-0-28-eps.html.
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.
Further Reading: What are gap-down stocks?
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.